Generex Biotechnology Corp. (fka GNBTQ)

[Rsarabjit]

GNBT / NGIO - NGIO Evaluated at 500 Million!

Link: https://www.otcmarkets.com/stock/GNBT/news/Generex-Biotechnology-Announces-Investor-Conference-Call-Scheduled-for-Friday-February-5-2021-at-900-AM?id=285672

We e have completed our ex vivo human trial of COVID-19 patient samples and can confirm that the results of the T cell activation and antibody screen have enabled us to select Ii-Key-SARS-CoV-2 epitopes for our vaccine formulation. I will provide an update on these results as well as the results of our ongoing immunogenicity study that will confirm the commercial viability of our Ii-Key vaccine. In addition, I will update everyone on our progress and timing on the NuGenerex Immuno-Oncology Nasdaq listing now that our third-party valuation analysis has been completed with a value estimated at over $500 million. This third-party valuation report is the last piece of information required to enable us to set the price per share to meet the standards for the Nasdaq. I will also provide a complete corporate update including discussions of our subsidiaries”.